News: Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

88.76EUR
19 Sep 2014
Price Change (% chg)

€0.30 (+0.34%)
Prev Close
€88.46
Open
€88.81
Day's High
€88.85
Day's Low
€87.97
Volume
5,495,625
Avg. Vol
2,539,989
52-wk High
€88.85
52-wk Low
€68.29

Search Stocks
Select another date:

Wed, Sep 17 2014

Sanofi unveils heart disease partnership with MyoKardia

PARIS - French drugmaker Sanofi announced on Wednesday a partnership with U.S.-based MyoKardia to develop therapies for patients with genetic heart diseases.

Sanofi unveils heart disease partnership with MyoKardia

PARIS, Sept 17 - French drugmaker Sanofi announced on Wednesday a partnership with U.S.-based MyoKardia to develop therapies for patients with genetic heart diseases.

Sanofi aims to grow Genzyme unit with new drugs and acquisitions

PARIS - (This story corrects the Sept.11 story. In the 10th paragraph, the quote should be attributed to Bill Sibold, not Mike Panzara)

CORRECTED-Sanofi aims to grow Genzyme unit with new drugs and acquisitions

(Corrects Sept.11 story. In 10th paragraph, quote should be attributed to Bill Sibold, not Mike Panzara)

Sanofi aims to grow Genzyme unit with new drugs and acquisitions

PARIS - Sanofi rare disease unit Genzyme hopes to become a leader in the multiple sclerosis (MS) field with the help of new products developed in-house but also through acquisitions, senior Genzyme executives told Reuters.

Sanofi says MS drug Lemtrada shows sustained effect on disease

PARIS - Sanofi rare disease unit Genzyme said its Lemtrada multiple sclerosis (MS) drug showed continued efficacy for four years in more than two thirds of patients and that no new safety risks had been identified in its latest studies.

Sanofi says MS drug Lemtrada shows sustained effect on disease

PARIS, Sept 11 - Sanofi rare disease unit Genzyme said its Lemtrada multiple sclerosis (MS) drug showed continued efficacy for four years in more than two thirds of patients and that no new safety risks had been identified in its latest studies.

Lilly, Boehringer copy of Sanofi's insulin gets EU approval

- Eli Lilly and Co and Boehringer Ingelheim said on Wednesday that the European Commission approved their copycat version of Sanofi SA's blockbuster insulin, Lantus.

Lilly, Boehringer copy of Sanofi's insulin gets EU approval

Sept 10 - Eli Lilly and Co and Boehringer Ingelheim said on Wednesday that the European Commission approved their copycat version of Sanofi SA's blockbuster insulin, Lantus.

Euro's slide revives hopes of European corporate profits recovery

* Recent drop in euro to translate into 3-6 pct rise in earnings

Select another date:
Search Stocks